Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Emendobio Inc. is managing 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 9 distinct examiners, meaning that each pending matter is being handled by a different individual. MOAZZAMI, NAGHMEH NINA is identified as the busiest examiner, though they are responsible for only 1 pending action within this set.
The portfolio's active matters are distributed among 6 distinct art units. This distribution shows that while the technology area is focused on Biotechnology & Pharmaceuticals, the 9 pending office actions are diverse enough to require review from 6 different administrative groups. The one-to-one ratio of 9 distinct examiners to 9 pending actions suggests a broad exposure to different examiner perspectives across the company's current patent applications.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| REGA, KYLE THOMAS | 1 | 63.0% | +41.7% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16202955 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS RHODOPSIN GENE | SHIN, DANA H | 6d |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 68d |
| 18715759 | Engineered High Activity Omni-79 Nuclease Variants | MOAZZAMI, NAGHMEH NINA | — |
| 18682982 | ENGINEERED HIGH FIDELITY OMNI-50 NUCLEASE VARIANTS | MCLEOD, AFRICA MHAIRIE | — |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | — |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16202955 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS RHODOPSIN GENE | SHIN, DANA H | 6d |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 68d |
| 18715759 | Engineered High Activity Omni-79 Nuclease Variants | MOAZZAMI, NAGHMEH NINA | — |
| 18682982 | ENGINEERED HIGH FIDELITY OMNI-50 NUCLEASE VARIANTS | MCLEOD, AFRICA MHAIRIE | — |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | — |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | — |
| 17775017 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE USING GUIDES 21-30 NUCLEOTIDES IN LENGTH | HUMPHRIES, NICHOLAS ADAM | — |
| 17428253 | NEW ENGINEERED HIGH FIDELITY CAS9 | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1636 | 2 |
| 1656 | 1 |
| 1637 | 1 |
| 1632 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715759 | Engineered High Activity Omni-79 Nuclease Variants | MOAZZAMI, NAGHMEH NINA | 1656 | §102§103§112 | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18682982 | ENGINEERED HIGH FIDELITY OMNI-50 NUCLEASE VARIANTS | MCLEOD, AFRICA MHAIRIE | 1635 | §101§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112 | Non-Final OA | 68d | Pending | Sep 21, 2023 |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 23, 2022 |
| 17775017 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE USING GUIDES 21-30 NUCLEOTIDES IN LENGTH | HUMPHRIES, NICHOLAS ADAM | 1631 | DP | Final Rejection | — | Pending | May 06, 2022 |
| 17428253 | NEW ENGINEERED HIGH FIDELITY CAS9 | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | — | Pending | Aug 03, 2021 |
| 16202955 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS RHODOPSIN GENE | SHIN, DANA H | 1635 | §103§112Other | Non-Final OA | 6d | Pending | Nov 28, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmendobio Inc. has 8 pending office actions as of October 2026, spread across 6 art units and 8 examiners.
Naghmeh Nina Moazzami has the most, with 1 of Emendobio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
